These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 26492560)

  • 1. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
    Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
    Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
    Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
    Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
    Schmidt-Hieber M; Fietz T; Knauf W; Uharek L; Hopfenmüller W; Thiel E; Blau IW
    Br J Haematol; 2005 Aug; 130(4):568-74. PubMed ID: 16098072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
    Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
    Kim SS
    Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of anti-CD25 monoclonal antibody used in treating steroid-resistant acute graft-versus-host disease following haploidentical bone marrow transplantation].
    Liu J; Wang HX; Duan LN; Yang HM; Xue M; Zhu L; Ding L; Wang ZD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):160-3. PubMed ID: 19236770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation.
    Jaiswal SR; Zaman S; Chakrabarti A; Sehrawat A; Bansal S; Gupta M; Chakrabarti S
    Transpl Immunol; 2016 Nov; 39():46-51. PubMed ID: 27577170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion.
    Chen HR; Ji SQ; Wang HX; Yan HM; Zhu L; Liu J; Xue M; Xun CQ
    Exp Hematol; 2003 Nov; 31(11):1019-25. PubMed ID: 14585364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Wang JZ; Liu KY; Xu LP; Liu DH; Chen YH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2008 Nov; 47(11):923-5. PubMed ID: 19080235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basiliximab Treatment for Patients With Steroid-Refractory Acute Graft-Versus-Host Disease Following Matched Sibling Donor Hematopoietic Stem Cell Transplantation.
    Jiang XY; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Sun YQ; Mo XD; Huang XJ
    Cell Transplant; 2024; 33():9636897241257568. PubMed ID: 38832653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease.
    Gao Z; Fan Z; Liu Z; Ye X; Zeng Y; Xuan L; Huang F; Lin R; Sun J; Liu Q; Xu N
    Front Immunol; 2024; 15():1408211. PubMed ID: 39021571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of severe intestinal acute graft-versus-host disease with CD25 monoclonal antibody in haploidentical hematopoietic stem cell transplantation].
    Chen HR; He XP; Yang K; Lou JX; Liu XD; Guo Z; Chen P; Liu B
    Zhonghua Yi Xue Za Zhi; 2010 Oct; 90(38):2693-6. PubMed ID: 21162899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of rituximab in chronic graft-versus-host disease.
    Bates JS; Engemann AM; Hammond JM
    Ann Pharmacother; 2009 Feb; 43(2):316-21. PubMed ID: 19193571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-CD25 monoclonal antibody with antithymocytic globulin for steroid-resistant severe acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation].
    Ye CX; Sun J; Liu QF; Qu H; Xu D; Zhang Y; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Dec; 28(12):2224-6. PubMed ID: 19114364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of steroid-resistant graft-versus-host disease after allogeneic bone marrow transplantation with anti-CD3/TCR monoclonal antibodies.
    Hebart H; Ehninger G; Schmidt H; Berner B; Reuss-Borst M; Waller HD; Müller CA; Einsele H
    Bone Marrow Transplant; 1995 Jun; 15(6):891-4. PubMed ID: 7581087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of gastrointestinal graft-versus-host disease according to the treatment response.
    Tamaki M; Nakasone H; Misaki Y; Yoshimura K; Gomyo A; Hayakawa J; Kusuda M; Akahoshi Y; Ishihara Y; Kawamura K; Tanihara A; Sato M; Terasako-Saito K; Kameda K; Wada H; Kikuchi M; Kimura SI; Kako S; Kanda Y
    Ann Hematol; 2018 Oct; 97(10):1951-1960. PubMed ID: 29860563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
    Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
    Front Immunol; 2021; 12():749266. PubMed ID: 34621279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis.
    Huang R; Tu S; Deng L; Kang Q; Song C; Li Y
    Hematology; 2015 Jul; 20(6):313-9. PubMed ID: 25321657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist.
    Funke VA; de Medeiros CR; Setúbal DC; Ruiz J; Bitencourt MA; Bonfim CM; Neto JZ; Pasquini R
    Bone Marrow Transplant; 2006 May; 37(10):961-5. PubMed ID: 16565744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.